drug_type
RELEVANT_DRUG
intervention_type
antibody-drug conjugate
drug_description
An anti-BCMA antibody–drug conjugate linking belantamab to the cytotoxic payload MMAF; after BCMA-mediated internalization, MMAF disrupts microtubules causing cell death, and the antibody retains Fc-mediated ADCC/ADCP.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
belantamab mafodotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Belantamab mafodotin is an anti-BCMA antibody–drug conjugate that binds BCMA on malignant plasma cells, is internalized, and releases the MMAF payload to inhibit microtubules and induce cell death; the afucosylated IgG1 antibody also engages Fc receptors to promote ADCC and ADCP.
drug_name
Belantamab mafodotin (GSK2857916)
nct_id_drug_ref
NCT05714839